CTOs on the Move

Pulmotect

www.pulmotect.com

 
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Pulmotect raised $12M on 03/23/2018

Similar Companies

VBI Vaccines

VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.

Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.

Rodin Therapeutics

Rodin Therapeutics is a Biotechnology company located in Cambridge, Massachusetts, United States.

Prolong Pharmaceuticals

Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.

Arch Therapeutics

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch`s development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2